XML 44 R37.htm IDEA: XBRL DOCUMENT v3.24.2.u1
License and Collaboration Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 12, 2024
Jul. 23, 2017
Apr. 30, 2018
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenue, excluding assessed tax       $ 23,489,000 $ 20,499,000 $ 45,128,000 $ 42,093,000  
Non-cash royalty revenue related to the sales of future royalties                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Revenue, excluding assessed tax       16,790,000 $ 15,832,000 32,298,000 $ 32,693,000  
Bristol Myers Squibb Company                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Sale of stock shares repurchased 8,300,000              
Sale of stock repurchased cash consideration $ 3,000,000              
Bristol Myers Squibb Company | Purchase Agreement                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Shares issued (in shares)     8,284,600          
Sale of stock consideration received     $ 850,000,000          
Other Partner                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Potential future additional payments for development milestones       $ 40,000,000   $ 40,000,000    
Nektar-358 | Eli Lilly                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Percentage of sharing in Phase 2 development costs   75.00%            
Nektar-358 | Maximum | Eli Lilly And Company                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Potential future additional development and regulatory milestones (up to)   $ 250,000,000            
Bristol Myers Squibb Collaboration Agreement                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Sale of stock shares repurchased 8,300,000              
Sale of stock repurchased cash consideration $ 3,000,000              
Nektar's | Nektar-358                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Received upfront and milestone payment   $ 150,000,000            
Percentage of sharing in Phase 2 development costs   25.00%            
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Upfront and milestone payments received from license agreements     $ 1,000,000,000          
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One                
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                
Potential future additional payments for development milestones               $ 50,000,000